亚洲与白人卵巢癌患者表现和生存差异:一项7914例患者的NRG Oncology/GOG辅助研究
该辅助研究汇总分析了1996至2011年十项前瞻性随机妇科肿瘤组一线临床试验的数据,比较亚洲与白人上皮性卵巢癌患者的特征与结局。7914例中白人7641例、亚洲273例;亚洲患者更年轻、体能状态更好、分期更早、透明细胞和黏液性组织学更多,5年疾病特异性生存54.1%高于白人46.1%,多因素分析中亚洲种族仍为全因生存的显著预后因素(HR 0.84)。
要点
- 亚洲患者更年轻、体能状态更好,I期占17.2%高于白人8.1%(p<0.001)
- 亚洲患者透明细胞癌15.8% vs 白人6.2%、黏液性癌3.3% vs 1.9%(p<0.001)
- 亚洲患者5年疾病特异性生存54.1% vs 白人46.1%(p=0.001)
核心结论
- 校正预后因素后,亚洲患者生存优于白人(全因生存HR 0.84;95%CI 0.72-0.99;p=0.04)。
研究设计与样本
- 十项前瞻性随机一线妇科肿瘤组临床试验(1996至2011年)的辅助汇总分析,共7914例,白人7641例、亚洲273例。
主要发现
- 亚洲患者入组时更年轻、体能状态更好、分期更早(I期17.2% vs 8.1%,p<0.001)。
- 亚洲患者透明细胞癌15.8% vs 6.2%、黏液性癌3.3% vs 1.9%(p<0.001)。
- 亚洲患者5年疾病特异性生存54.1% vs 白人46.1%(p=0.001)。
- 多因素分析中亚洲种族仍为全因生存的显著预后因素(HR 0.84;95%CI 0.72-0.99;p=0.04)。
- 其他与生存改善相关的因素包括更年轻、体能状态更好、满意减瘤、分期更早、非透明细胞组织学和更低级别肿瘤。
关键数值与推荐
- 亚洲患者5年疾病特异性生存54.1%,白人46.1%(p=0.001)。
- 全因生存多因素分析:亚洲种族HR 0.84(95%CI 0.72-0.99;p=0.04)。
- I期比例:亚洲17.2% vs 白人8.1%(p<0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare patient/tumor characteristics and outcomes of Asians to Caucasian patients with epithelial ovarian cancer. METHODS: Ancillary data were pooled and analyzed from ten prospective randomized front-line Gynecologic Oncology Group clinical trials from 1996 to 2011. Demographic, clinicopathologic features, disease-specific and all-cause survival were analyzed. RESULTS: Of 7914 patients, 7641 were Caucasian and 273 Asian. When compared to Caucasians, Asians were younger at trial enrollment, had a better performance status, earlier-stage cancers (17.2% vs. 8.1% with stage I; p < 0.001), and were more likely to be of clear cell (15.8% vs. 6.2%, p < 0.001) and mucinous (3.3% vs. 1.9%, p < 0.001) histology. Asians had an improved 5-year disease-specific survival of 54.1% compared to 46.1% for Caucasians, p = 0.001. In multivariate analysis, the Asian race remained a significant prognostic factor for all-cause survival (HR: 0.84; 95% CI: 0.72-0.99; p = 0.04). Other factors predictive of improved survival included younger age, better performance status, optimal cytoreduction, earlier stage, non-clear cell histology, and lower grade tumors. CONCLUSION: Asians enrolled into phase III ovarian cancer clinical trials were younger, with better performance status, earlier-stage of disease, and have a greater number of clear cell and mucinous tumors. After adjusting for these prognostic factors, Asians have a better survival compared to Caucasians.
引用
- Fuh KC, Java JJ, Chan JK, et al. Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. Gynecol Oncol. 2019. PMID: 31229298. doi:10.1016/j.ygyno.2019.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。